News

Underwriters Exercise Option for 537,300 Shares of Common Stock, Increasing Total Aggregate Proceeds to Approximately $103.0 Million MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the closing of its public offering of 4,119,300 shares of its common stock at a public offering price of $25.00 per share, including 537,300 shares sold pursuant to the underwriters' option to purchase additional shares. This public offering resulted in total aggregate proceeds of approximately $103.0 million, before underwriting discounts and expenses.

DURHAM, N.C., June 8, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today the successful enrollment of the targeted 450 patients in SUPPRESS, the Phase 3 trial evaluating brincidofovir for the prevention of clinically significant cytomegalovirus (CMV) infection in hematopoietic cell transplant (HCT), also known as bone marrow or stem cell transplant recipients. The company anticipates reporting topline data from SUPPRESS in early 2016.

June 5, 2015 – Ithaca, NY – Advion, Inc., a leading systems and consumables developer for the life sciences industry, announces it has signed a definitive agreement to be acquired by Bohui with an expected close date on June 30, 2015. The acquisition is strategic for both companies and will enable Advion to broaden its investments in the areas of life science, clinical, and food safety applications. Advion will continue to trade under its current name and brand, with all employees and executives remaining with the company. All three (3) operations and locations in Ithaca, NY are expected to remain unchanged into the future.

-- First Patient-Side Robotically Enhanced Laparoscopic Surgery Platform -- RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced the submission of its 510(k) application with the U.S. Food and Drug Administration (FDA) for clearance of the company's SurgiBot™ System.

Approval marks the First Approved Combination and First Approved Sumatriptan Migraine Product for Patients Age 12-17 MORRISTOWN, NJ – May 15, 2015 – Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved TREXIMET® (sumatriptan and naproxen sodium) for use in pediatric patients 12 years of age and older for the acute treatment of migraine with or without aura.

CoolSculpting Procedure Continues to Grow Noninvasive Fat Reduction Market PLEASANTON, CA -- (Marketwired) -- 05/14/15 -- ZELTIQ® Aesthetics, Inc. (NASDAQ: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, today announced it recently shipped its 2,000,000th CoolSculpting treatment cycle.

-CD101 IV designated for treatment of serious or life-threatening Candida infections- SAN DIEGO--(BUSINESS WIRE)--May 11, 2015-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced that the U.S. Food and Drug Administration (FDA) has designated the company’s lead antifungal product candidate, CD101 IV, as a Qualified Infectious Disease Product (QIDP) with Fast Track status. The QIDP and Fast Track designations are for the use of CD101 IV in the treatment of candidemia and invasive candidiasis.

MORRISTOWN, NJ – (BUSINESS WIRE) – May 05, 2015 – Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the successful completion of a human pharmacokinetic equivalence study with ZX007, an innovative abuse deterrent tablet formulation of hydrocodone bitartrate. The clinical study evaluated the pharmacokinetics and safety of prototype formulations developed by Altus Formulation using its proprietary INTELLITAB™ technology, for comparison with Zohydro® ER, resulting in the selection of the final ZX007 prototype for pivotal clinical studies. Damon Smith, CEO of Altus Formulation said; “We are very happy that ZX007 is performing in the way we expected in human studies and we look forward to working with the Pernix team to complete development”.

BOSTON, May 5, 2015 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a pharmaceutical company focused on the development and commercialization of innovative, antibacterial therapies based upon tetracycline chemistry, has completed its previously announced offering of 3,089,000 shares of common stock at a public offering price of $24.50, which includes 229,000 shares of common stock issued upon the exercise, in part, by the underwriters of an option to purchase additional shares from Paratek. The aggregate net proceeds before expenses to Paratek are approximately $71.1 million, after deducting underwriting discounts and commissions.

New Formulation Maintains 12-Hour Efficacy to Treat Patients Suffering from Chronic Pain MORRISTOWN, NJ – (BUSINESS WIRE) – May 04, 2015 – Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that the new formulation of Zohydro® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, with BeadTek™ is now available in U.S. pharmacies. On January 30, 2015, the U.S. Food and Drug Administration (FDA) approved this updated formulation that features BeadTek, a technology encompassing an indistinguishable mix of inactive beads, active immediate-release hydrocodone beads and active extended-release hydrocodone beads. Zohydro ER with BeadTek delivers an extended release of hydrocodone that provides 12-hour dose duration. When taken as directed, the inactive beads contained in Zohydro ER with BeadTek remain inert. The inactive beads dissolve independently of the active hydrocodone beads and are designed not to change the 12-hour release properties of the medication when taken as directed. However, when crushed and dissolved in liquids or solvents, the inactive beads are designed to immediately form a viscous gel.